2:15 PM
 | 
Mar 12, 2019
 |  BC Extra  |  Politics & Policy

FDA looks to broaden cancer trial eligibility

In an attempt to accelerate development of cancer therapies for under-represented patient populations, FDA is aiming to expand eligibility criteria to increase enrollment of children, adolescents and other patient groups in trials of cancer drugs. The agency released four draft guidances Tuesday with suggested eligibility criteria for including pediatric patients ages...

Read the full 240 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$50 USD
More Info >